Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 84

  • 3 924 clinical trials
  • 1 545 recruiting
  • 706 conditions
  • 31 countries

Conditions in this area

706 conditions with trials, the busiest first

Non-small cell lung cancer332Breast cancer170Plasma cell myeloma164Neoplasm158Acute myeloid leukaemia132Neoplasm malignant129Colorectal cancer metastatic106Prostate cancer102Colorectal cancer90Ovarian cancer90Hepatocellular carcinoma89Breast cancer metastatic84Non-small cell lung cancer metastatic82Chronic lymphocytic leukaemia80Malignant melanoma79Triple negative breast cancer69Squamous cell carcinoma of head and neck68Hormone receptor positive HER2 negative breast cancer62Non-small cell lung cancer stage IV59Pancreatic carcinoma57Hormone-refractory prostate cancer56Bladder cancer55Gastric cancer55Endometrial cancer53+682

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 924 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 924 clinical trials

Gastroenteropancreatic neuroendocrine tumour disease

Recruiting

Study of Intra-Arterial Infusion of Lutetium (177Lu) Oxodotreotide for Adults with Gastroenteropancreatic Neuroendocrine Tumors with Liver Metastases

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Loperamide Hydrochloride
  • Sponsor:Centre Hospitalier Universitaire De Bordeaux

Study on Pembrolizumab and Radiotherapy for Patients with High-Risk Soft Tissue Sarcoma in the Limbs

Recruiting
Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Fondazione IRCCS Istituto Nazionale Dei Tumori

Breast cancer+4

Recruiting

Study on zAvatar Test for Treatment Decisions in Relapsed Ovarian Cancer and Metastatic Breast Cancer Using Palbociclib and Drug Combination for Eligible Patients

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Champalimaud Clinical Centre

Indolent systemic mastocytosis

Recruiting

Study of Elenestinib for Patients with Indolent Systemic Mastocytosis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Sponsor:Blueprint Medicines Corp.

Prostate cancer+1

Recruiting

Study on Darolutamide, Triptorelin, and Leuprorelin Acetate for Patients with Newly Diagnosed Prostate Cancer and Pelvic Lymph Node Metastases

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:ARTIC

B-cell lymphoma recurrent+1

Recruiting

Study on the Safety and Effectiveness of MB-CART2019.1, Fludarabine, and Cyclophosphamide in Children with Relapsed or Refractory B Cell Neoplasms

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Sponsor:Miltenyi Biomedicine GmbH

Colorectal cancer

Recruiting

Study on the Effects of Aspirin and Omeprazole in Obese and Non-Obese Patients with Colorectal Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Fundacion Instituto De Investigacion Sanitaria Aragon

Hodgkin's disease refractory

Recruiting

Study of Nivolumab and Chemotherapy Combination for Patients with Refractory Hodgkin's Lymphoma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Sponsor:Medical University Of Gdansk

Chronic myeloid leukaemia

Recruiting

Study of asciminib treatment for patients with Chronic Myeloid Leukemia who have T315I mutation and cannot take or tolerate ponatinib

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Novartis Pharma S.A.S.

Study of Pembrolizumab Combined with Standard Chemo-Radiotherapy for Newly Diagnosed Glioblastoma Multiforme Patients

Recruiting
Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Sponsor:Agencja Badań Medycznych

Hepatoblastoma

Recruiting

Study on Doxorubicin, Fluorouracil, and Oxaliplatin for Children and Adolescents with Primary Malignant Liver Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years
  • Sponsor:Medical University Of Gdansk

Neoplasm malignant

Recruiting

Study of Drug Combination for Advanced Cancer Patients with Known Molecular Profile - FINPROVE Study

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:HUS-Yhtymae

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Infliximab65 clinical trialsVincristine Sulfate55 clinical trialsAbemaciclib45 clinical trialsIbrutinib43 clinical trialsTrifluridine31 clinical trialsAvelumab30 clinical trialsApalutamide27 clinical trialsAmivantamab25 clinical trialsZanubrutinib24 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.